NewAmsterdam Pharma N.V. - NAMS Quarterly EPS earnings growth

NewAmsterdam Pharma Corp - graphic logo of issuer NAMS

NewAmsterdam Pharma (NAMS) is fighting for the cardiometabolic market amid intense pressure from low-cost generics. Quarterly earnings per share growth reflects the depth of the revenue decline, while the 76.10 metric serves as the target level. The development of a breakthrough CETP inhibitor provides a technological leap, and successful clinical trials strengthen the medical community's confidence in this young biopharmaceutical brand.

NewAmsterdam Pharma Company N.V. (NAMS) - Year-over-year earnings per share growth for the last twelve months from 06/21/2023 to 11/17/2026

Financial and market metric breakdowns for NewAmsterdam Pharma (NAMS)

Analysis of all company metrics:NewAmsterdam Pharma
Manufactured product of NewAmsterdam Pharma Corp

Quarterly EPS growth measures the rate of change in net income per share, reflecting the actual acceleration of the business. Investors utilize this calculation to identify consolidation phases or momentum-driven capitalization growth. When analyzing the quarterly EPS chart, level breakouts should be confirmed by trading volumes. The stability of the biopharmaceutical sector minimizes geopolitical risks for NewAmsterdam Pharma (NAMS). This ensures the predictability of fundamental metrics during the development of global drugs.

Competitors of NewAmsterdam Pharma (NAMS)

ASND (Ascendis Pharma) - Year-over-year net earnings per share growth for the last 12 months|MDGL: Year-over-year earnings per share growth rate for the last twelve months|CORT (Corcept Therapeutics Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Rhythm Pharmaceuticals|Quarterly EPS earnings growth AKRO|Year-over-year earnings per share growth for the last twelve months MTSR (Metsera, Inc.)|Year-over-year earnings per share growth for the last twelve months moonlaketx.com MLTX|Crinetics Corp (CRNX) - Earnings per share growth in annualized terms for the last twelve months|SLNO - Year-over-year earnings per share growth for the last twelve months|FOLD: Year-over-year earnings per share growth for the last twelve months|ETNB: Quarterly EPS earnings growth|AGIO - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Structure Corp|MiMedx Corp (MDXG) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months rezolutebio.com (RZLT)|Year-over-year net earnings per share growth for the last 12 months lexpharma.com LXRX|Quarterly EPS earnings growth MBX (MBX Biosciences)|Altimmune Corp - Year-over-year earnings per share growth for the last twelve months|Aardvark Therapeutics Inc. - Quarterly EPS earnings growth|SGMT - Quarterly EPS earnings growth|BioAge Labs (BIOA) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months biomeafusion.com (BMEA)|Year-over-year earnings per share growth for the last twelve months Quince Therapeutics, Inc.|Year-over-year net earnings per share growth for the last 12 months Fractyl (GUTS)|Year-over-year net earnings per share growth for the last 12 months VTVT (vTv Therapeutics Inc.)|ATPC - Earnings per share growth in annualized terms for the last twelve months|Pluri Inc. - Year-over-year net earnings per share growth for the last 12 months|Net earnings per share growth for the trailing year Synlogic Corp|LPCN - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Matinas BioPharma Holdings, Inc. MTNB|SPRB: Quarterly EPS earnings growth|Galecto Corp - Year-over-year earnings per one share growth for the last 12 months|CTCX (carmellrx.com) - Quarterly EPS earnings growth|Quarterly EPS earnings growth lumos-pharma.com|Quarterly EPS earnings growth ONVO|Year-over-year net earnings per share growth for the last 12 months Radius Health RDUS